This study aims to evaluate the absorption, metabolism, and excretion of a single oral dose of \[¹⁴C\]SSS17 in healthy adult Chinese male subjects, elucidating its overall pharmacokinetic profile in humans to provide essential information for its rational clinical use.
Healthy adult male subjects aged 18-45 years .
Body weight ≥50 kg .
Normal findings on comprehensive health assessment.
The subject demonstrates understanding of the trial's objectives, requirements, procedures, and potential adverse reactions; voluntarily participates; commits to complete all trial activities per protocol and comply with study regulations; with the informed consent process conducted in compliance with Good Clinical Practice ."
Subjects with abnormalities in the nervous system, respiratory system, cardiovascular system, digestive system, hematological and lymphatic systems, endocrine system, or musculoskeletal system that are deemed clinically significant by the investigator.
History of organic heart disease
History of hypersensitivity or allergy to active ingredients.
Average daily smoking >5 cigarettes within 3 months prior to screening or inability to abstain during the trial.
Single group
[14C]SSS17
Drugsingle oral dose
Cumulative excretion rate of radioactivity in excreta (urine, feces) and total radioactivity (urine and feces)
Cmax
Tmax
AEs
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
